Plant-made vaccines against West Nile virus are potent, safe, and economically feasible

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The threat of West Nile virus (WNV) epidemics with increasingly severe neuroinvasive infections demands the development and licensing of effective vaccines. To date, vaccine candidates based on inactivated, live-attenuated, or chimeric virus, and viral DNA and WNV protein subunits have been developed. Some have been approved for veterinary use or are under clinical investigation, yet no vaccine has been licensed for human use. Reaching the milestone of a commercialized human vaccine, however, may largely depend on the economics of vaccine production. Analysis suggests that currently only novel low-cost production technologies would allow vaccination to outcompete the cost of surveillance and clinical treatment. Here, we review progress using plants to address the economic challenges of WNV vaccine production. The advantages of plants as hosts for vaccine production in cost, speed and scalability, especially those of viral vector-based transient expression systems, are discussed. The progress in developing WNV subunit vaccines in plants is reviewed within the context of their expression, characterization, downstream processing, and immunogenicity in animal models. The development of vaccines based on enveloped and non-enveloped virus-like particles is also discussed. These advancements suggest that plants may provide a production platform that offers potent, safe and affordable human vaccines against WNV.

Original languageEnglish (US)
Pages (from-to)671-680
Number of pages10
JournalBiotechnology Journal
Volume10
Issue number5
DOIs
StatePublished - May 1 2015

Fingerprint

West Nile Virus Vaccines
Vaccines
West Nile virus
Costs and Cost Analysis
Economics
Subunit Vaccines
Viral DNA
Protein Subunits
Licensure
Virion
Vaccination
Animal Models
Viruses
Technology

Keywords

  • Nicotiana benthamiana
  • Plant biotechnology
  • Plant-made vaccines
  • Vaccine
  • West Nile virus (WNV)

ASJC Scopus subject areas

  • Applied Microbiology and Biotechnology
  • Molecular Medicine

Cite this

Plant-made vaccines against West Nile virus are potent, safe, and economically feasible. / Chen, Qiang.

In: Biotechnology Journal, Vol. 10, No. 5, 01.05.2015, p. 671-680.

Research output: Contribution to journalArticle

@article{961291af0c3c441787171784615a31a3,
title = "Plant-made vaccines against West Nile virus are potent, safe, and economically feasible",
abstract = "The threat of West Nile virus (WNV) epidemics with increasingly severe neuroinvasive infections demands the development and licensing of effective vaccines. To date, vaccine candidates based on inactivated, live-attenuated, or chimeric virus, and viral DNA and WNV protein subunits have been developed. Some have been approved for veterinary use or are under clinical investigation, yet no vaccine has been licensed for human use. Reaching the milestone of a commercialized human vaccine, however, may largely depend on the economics of vaccine production. Analysis suggests that currently only novel low-cost production technologies would allow vaccination to outcompete the cost of surveillance and clinical treatment. Here, we review progress using plants to address the economic challenges of WNV vaccine production. The advantages of plants as hosts for vaccine production in cost, speed and scalability, especially those of viral vector-based transient expression systems, are discussed. The progress in developing WNV subunit vaccines in plants is reviewed within the context of their expression, characterization, downstream processing, and immunogenicity in animal models. The development of vaccines based on enveloped and non-enveloped virus-like particles is also discussed. These advancements suggest that plants may provide a production platform that offers potent, safe and affordable human vaccines against WNV.",
keywords = "Nicotiana benthamiana, Plant biotechnology, Plant-made vaccines, Vaccine, West Nile virus (WNV)",
author = "Qiang Chen",
year = "2015",
month = "5",
day = "1",
doi = "10.1002/biot.201400428",
language = "English (US)",
volume = "10",
pages = "671--680",
journal = "Biotechnology Journal",
issn = "1860-6768",
publisher = "Wiley-VCH Verlag",
number = "5",

}

TY - JOUR

T1 - Plant-made vaccines against West Nile virus are potent, safe, and economically feasible

AU - Chen, Qiang

PY - 2015/5/1

Y1 - 2015/5/1

N2 - The threat of West Nile virus (WNV) epidemics with increasingly severe neuroinvasive infections demands the development and licensing of effective vaccines. To date, vaccine candidates based on inactivated, live-attenuated, or chimeric virus, and viral DNA and WNV protein subunits have been developed. Some have been approved for veterinary use or are under clinical investigation, yet no vaccine has been licensed for human use. Reaching the milestone of a commercialized human vaccine, however, may largely depend on the economics of vaccine production. Analysis suggests that currently only novel low-cost production technologies would allow vaccination to outcompete the cost of surveillance and clinical treatment. Here, we review progress using plants to address the economic challenges of WNV vaccine production. The advantages of plants as hosts for vaccine production in cost, speed and scalability, especially those of viral vector-based transient expression systems, are discussed. The progress in developing WNV subunit vaccines in plants is reviewed within the context of their expression, characterization, downstream processing, and immunogenicity in animal models. The development of vaccines based on enveloped and non-enveloped virus-like particles is also discussed. These advancements suggest that plants may provide a production platform that offers potent, safe and affordable human vaccines against WNV.

AB - The threat of West Nile virus (WNV) epidemics with increasingly severe neuroinvasive infections demands the development and licensing of effective vaccines. To date, vaccine candidates based on inactivated, live-attenuated, or chimeric virus, and viral DNA and WNV protein subunits have been developed. Some have been approved for veterinary use or are under clinical investigation, yet no vaccine has been licensed for human use. Reaching the milestone of a commercialized human vaccine, however, may largely depend on the economics of vaccine production. Analysis suggests that currently only novel low-cost production technologies would allow vaccination to outcompete the cost of surveillance and clinical treatment. Here, we review progress using plants to address the economic challenges of WNV vaccine production. The advantages of plants as hosts for vaccine production in cost, speed and scalability, especially those of viral vector-based transient expression systems, are discussed. The progress in developing WNV subunit vaccines in plants is reviewed within the context of their expression, characterization, downstream processing, and immunogenicity in animal models. The development of vaccines based on enveloped and non-enveloped virus-like particles is also discussed. These advancements suggest that plants may provide a production platform that offers potent, safe and affordable human vaccines against WNV.

KW - Nicotiana benthamiana

KW - Plant biotechnology

KW - Plant-made vaccines

KW - Vaccine

KW - West Nile virus (WNV)

UR - http://www.scopus.com/inward/record.url?scp=84928825678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928825678&partnerID=8YFLogxK

U2 - 10.1002/biot.201400428

DO - 10.1002/biot.201400428

M3 - Article

VL - 10

SP - 671

EP - 680

JO - Biotechnology Journal

JF - Biotechnology Journal

SN - 1860-6768

IS - 5

ER -